Next-Generation Bispecific Nanobody Immunotherapy Targeting CD40 and TNFRSF9 for Colorectal Cancer

VHH-P816 represents an innovative, fully humanized single-domain antibody (nanobody) strategically engineered to target both the CD40 molecule (CD40) and the TNF receptor superfamily member 9 (TNFRSF9). Currently advancing through Biological Testing, this tetravalent, bispecific agonist antibody harnesses a unique fusion to a silenced IgG1 Fc region, aiming to deliver potent immune modulation. VHH-P816 holds significant therapeutic promise for colorectal cancer by activating key immune co-stimulatory pathways, potentially transforming immunotherapeutic strategies in this indication.

Licensing Opportunity

VHH-P816 is actively open for out-licensing and strategic collaboration opportunities. We welcome partners interested in advancing this differentiated immunotherapeutic asset towards clinical and commercial development in oncology.

Development Phase

Modality

VHH-P816 is a tetravalent, bispecific single-domain agonist antibody that specifically targets CD40 and TNFRSF9. As a nanobody, its compact single-domain architecture offers superior tissue penetration, intrinsic stability, and solubility compared to conventional antibodies. The molecule is precisely designed with dual agonist functionality and fused to a silenced IgG1 Fc region, reducing unwanted immune effector functions while maintaining extended serum half-life. These structural advantages facilitate enhanced immune cell activation in the tumor microenvironment and may translate into improved anti-tumor efficacy for patients with colorectal cancer, especially in solid tumor settings where robust tissue accessibility and durable activity are essential.

Target

CD40 and TNFRSF9 are pivotal immune co-stimulatory receptors belonging to the tumor necrosis factor receptor superfamily. CD40 is primarily expressed on antigen-presenting cells such as dendritic cells, B cells, and macrophages, and is instrumental in promoting adaptive immune responses. TNFRSF9 is predominantly found on activated T cells and natural killer cells, serving as a critical mediator of T cell proliferation and survival. Both CD40 and TNFRSF9 have been validated as relevant targets in colorectal cancer, as their activation is associated with enhancing anti-tumor immunity and overcoming tumor-induced immunosuppression. The dual targeting strategy of VHH-P816 against CD40 and TNFRSF9 therefore provides a strong strategic advantage, aiming to orchestrate a coordinated immune response against malignancies like colorectal cancer.

Mechanism of Action

VHH-P816 exerts its biological effects by simultaneously engaging and activating CD40 and TNFRSF9 on relevant immune cell populations. By acting as an agonist to both CD40 and TNFRSF9, VHH-P816 promotes signal transduction pathways that enhance dendritic cell maturation, augment antigen presentation, and drive T cell expansion and effector functions. These mechanisms underpin a heightened adaptive immune response against tumor cells in colorectal cancer. Furthermore, as a nanobody platform, VHH-P816 offers versatility for future therapeutic innovations, including potential development as a delivery vehicle for antibody-drug conjugates, bispecifics, or multi-specific immunotherapeutics.

Colorectal Cancer

Colorectal cancer is among the most common malignancies worldwide, representing a substantial proportion of global cancer incidence and mortality. Risk factors include lifestyle, genetic predisposition, and environmental influences. Current standard-of-care regimens encompass surgical resection, chemotherapy, radiotherapy, and targeted therapies focusing on critical signaling pathways and immune checkpoints. While these approaches have improved clinical outcomes for some patient populations, significant challenges persist. Limitations include resistance to therapy, adverse toxicities, and insufficient response rates, particularly in advanced or metastatic disease settings. The increasing recognition of the role of immune modulation in colorectal cancer has underscored the need for effective immunotherapeutic strategies. VHH-P816, by targeting CD40 and TNFRSF9, is positioned to address unmet needs in colorectal cancer therapy, leveraging dual co-stimulatory pathways to potentiate anti-tumor immune responses and potentially offer an alternative for patients who lack durable responses to current treatment modalities.